Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are... see more

Recent & Breaking News (NDAQ:ALDX)

Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting

PR Newswire October 24, 2017

Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day

PR Newswire October 10, 2017

Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting

PR Newswire October 5, 2017

Aldeyra Therapeutics Announces 2017 Research and Development Day

PR Newswire September 27, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  September 22, 2017

19 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  September 22, 2017

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

PR Newswire September 21, 2017

Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 20, 2017

Mid-Day Market Update: Bob Evans Farms Rises On Acquisition News; Mediwound Shares Plunge

Benzinga.com  September 19, 2017

Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

PR Newswire September 19, 2017

Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire September 18, 2017

FinancialInsiders.com Earnings Recap Week Ending September 15th, 2017

PR Newswire September 15, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  September 13, 2017

14 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  September 12, 2017

Mid-Day Market Update: Advaxis Drops Following Q3 Results; Aethlon Medical Shares Climb

Benzinga.com  September 12, 2017

Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial

PR Newswire September 12, 2017

Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial

PR Newswire September 11, 2017

Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results

PR Newswire August 8, 2017

Investor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call

Accesswire August 8, 2017

Aldeyra Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference

PR Newswire August 3, 2017